Mankind Pharma Holds 35th AGM on Aug 4, 2026; Discusses FY26 Financials
Mankind Pharma Limited conducted its 35th AGM on August 4, 2026, discussing FY26 financials and approving key resolutions including financial statements and director re-appointments. The meeting was held via video conference, with updates provided by the CEO and CFO.
The AGM is a standard annual event to discuss past performance and appoint directors. The information shared, such as the adoption of financial statements and director re-appointments, is procedural and does not introduce new material information that would significantly impact the company's stock or business operations.
The announcement pertains to the proceedings of the Annual General Meeting, which is a routine corporate event. It details the discussions and resolutions passed but does not contain any new financial performance data or strategic announcements that would significantly alter the company's outlook.
Mankind Pharma Limited held its Thirty-Fifth Annual General Meeting (AGM) on Tuesday, August 4, 2026, from 3:30 P.M. to 4:56 P.M. IST, conducted through Video Conferencing (VC) as per regulatory guidelines. The meeting was presided over by Executive Chairman Mr. Ramesh Juneja, with the CEO & Whole-time Director Mr. Sheetal Arora providing business operations updates and Global Chief Financial Officer Mr. Ashutosh Dhawan presenting the financials for the financial year 2025-26. Key agenda items included the adoption of standalone and consolidated audited financial statements for the year ended March 31, 2026, the re-appointment of Mr. Rajeev Juneja as Director, the re-appointment of Mr. Satish Kumar Sharma as Whole-time Director, and the ratification of cost auditors' remuneration for FY 2026-27. Remote e-voting was available from August 1 to August 3, 2026, with an additional e-voting facility during the AGM. The results of the e-voting on all resolutions, along with the consolidated scrutinizer's report, will be filed with the stock exchanges and published on the company's website and CDSL.
Several directors and key officials attended the AGM virtually, including Mr. Ramesh Juneja (Executive Chairman), Mr. Sheetal Arora (CEO & Whole-time Director), Ms. Vijaya Sampath (Independent Director), Mr. T. P. Ostwal (Independent Director), Mr. Bharat Anand (Independent Director), Mr. Vivek Kalra (Independent Director), Mr. Satish Kumar Sharma (Whole-time Director), Mr. Ashutosh Dhawan (Global CFO), and Mr. Hitesh Kumar Jain (Company Secretary & Compliance Officer). Mr. Rajeev Juneja, Vice Chairman and Managing Director, could not attend due to a family bereavement. The meeting concluded with the Chairman thanking members for their participation and constructive suggestions.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.